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Purpose: The purpose of the present study was to determine the role of the tumor necrosis factor alpha (TNF-α) gene
polymorphism G-308A and total serum immunoglobulin E (TsIgE) levels in the onset of pseudoexfoliation glaucoma
(PEXG) in Pakistani patients.
Methods: The TNF-α polymorphism G-308A was analyzed in 122 patients with PEXG and 126 healthy unrelated controls
by using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). TsIgE levels were
determined by solid-phase enzyme-linked immunosorbent assay (ELISA).
Results: The AA and GA genotypes were strongly associated with PEXG (p<0.001), with an odds ratio (OR) of 0.07
(95% confidence interval [CI]=0.02-0.27) and 0.24 (95% CI=0.12-0.51), respectively, while the GG genotype was found
at a higher frequency in controls as compared to patients (p<0.001) OR=8.95 (95% CI=4.55–17.81). No significant
difference was found in TsIgE levels of both patients and controls (p=0.86).
Conclusion: The present study concludes that the TNF-α polymorphism G-308A is strongly associated with PEXG. To
our knowledge this is the first study in southeast Asia which demonstrates a strong association of a TNF-α polymorphism
with PEXG.
Pseudoexfoliation syndrome (PEX) was first described
by Lindberg in 1917 and involves excessive production and
progressive accumulation of fibrillar extracellular material in
various tissues [1,2]. Although the syndrome is recognized to
be a systemic disorder, it is the most common identifiable
cause  of  glaucoma  that  has  now  been  termed
pseudoexfoliation glaucoma (PEXG) [2–4].
PEX  syndrome  occurs  worldwide  but  its  prevalence
varies among different age groups, races, and geographical
locations.  The  highest  prevalence  of  20–70%  has  been
reported in elderly people (70–80 years) and it is estimated
that PEXG affects 10– 20% of all individuals above 60 years
of age. Moreover, prevalence varies in different countries with
the highest rate of about 46.9% in Greece [5]. Comprehensive
data on the prevalence of PEXG in Pakistan is not available.
However,  a  recently  conducted  hospital-based  study  did
reveal a high rate of PEXG (6.45%) among patients with
ocular  ailments  [6].  The  mechanism  underlying  the
development  of  PEX  syndrome  and  its  subsequent
progression  to  PEXG  is  still  unclear  [4,7].  Studies  have
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focused  on  immunological  changes  during  glaucomatous
pathogenesis and possible preventive therapies based along
those lines have been proposed. The major targets of interest
are cytokines, as recent advances reveal that they play an
important  role  in  the  pathogenesis  of  glaucoma  and  may
regulate retinal ganglion cell (RGC) survival or death [8].
Tumor necrosis factor alpha (TNF-α), a proinflammatory
cytokine,  is  upregulated  in  several  neurodegenerative
disorders including multiple sclerosis, Parkinson’s disease,
Alzheimer’s disease [9,10] and in optic nerve microglia and
astrocytes in glaucoma patients [11,12]. It has been observed
that  both  mRNA  and  protein  levels  of  TNF-α  or  TNF-α
receptor-1 (TNF-R1) are raised in the retina of glaucomatous
eyes  as  compared  to  normal  eyes,  and  therefore  it  was
suggested that cell death mediated by TNF-α is a contributing
factor  in  the  neurodegeneration  in  glaucoma  [13].  Using
animal  models,  Nakazawa  et  al.  [14]  showed  that  ocular
hypertension or increased intraocular pressure induces TNF-
α upregulation in the retina, which in turn leads to RGC
degeneration. Moreover, it has been observed that anti-TNF-
α antibodies can prevent death of RGCs by reducing ocular
hypertension, suggesting that reducing the expression of TNF-
α would be beneficial in treating glaucoma [14].
Several  polymorphisms  have  been  identified  in  the
upstream  regulatory  region  of  TNF-α.  Among  these  is  a
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2861common  biallelic  G  (TNF1  allele)  transition  to  A  (TNF2
allele)  308  (rs1800629)  nucleotide  upstream  from  the
transcription  initiation  site  in  the  TNF-α  promoter.  This
transition  is  considered  to  be  an  important  enhancer  of
transcriptional activation associated with elevated levels of
TNF-α  [15],  which  have  been  shown  to  be  involved  in
increased susceptibility to different eye diseases including
diabetic  retinopathy  and  glaucoma  [16–18].  Association
studies of the G-308A polymorphism in different populations
have  shown  contradictory  results  [19,20].  Therefore,
additional  comprehensive  studies  involving  different
populations are warranted to better understand the role of
TNF-α polymorphisms in different diseases. The aim of the
present  study  was  to  study  the  association  of  the  TNF-α
polymorphism  G-308A  with  PEXG  in  the  Pakistani
population.
METHODS
This was a multicenter case-control study that included 122
PEXG patients and 126 controls. The study was approved by
the Departmental Ethical Committee of COMSATS Institute
of Informational Technology and the relevant hospital ethics
committees,  and  conformed  to  the  principles  of  the
Declaration of Helsinki. PEXG patients were recruited from
the outpatient departments of two major eye clinics including
Al-Shifa Eye Trust Hospital, Rawalpindi, and Christian Eye
Hospital, Taxila. The healthy control individuals did not have
any exfoliation material in the eye or any other evidence of
glaucoma, and had normal visual fields.
All the PEXG patients underwent a complete ophthalmic
examination including tonometric assessment of intraocular
pressure (IOP), measurement of cup to disk ratio (CDR), and
slit lamp biomicroscopy. Patients were evaluated by slit lamp
biomicroscopy for the presence of exfoliative material along
the papillary border and on the iris without dilating the eye.
After pupil dilation the patients were also analyzed for the
presence  of  white  material  deposits  on  the  anterior  lens
surface. Gonioscopy was performed in all patients with a high
magnification  lens  for  determination  of  the  angle.
Approximately  4–6  ml  of  venous  blood  was  obtained  in
vacutainers (product no 364606, Becton Dickinson, Franklin
Lakes,  NJ)  containing  acid  citrate  dextrose  (ACD)  as
anticoagulant, after obtaining informed written consent from
the subjects. For the ELISA assay, serum was obtained from
clotted  blood  collected  in  Z-serum  sep  clot-activator
vacutainer tubes (Greiner Bio-One, Munich, Germany) by
centrifuging the vacutainers at 3,000 rpm for 10 min.
Genomic  DNA  was  isolated  by  a  standard  phenol–
chloroform  extraction  method.  A  212  bp  DNA  sequence
corresponding to the promoter region of TNF-α was amplified
using the forward primer 5′-AGG CAA TAG GTT TTG AGG
GCC AT-3′ and the reverse primer 5′-GTA GTG GGC CCT
GCA CCT TCT-3′ [21]. The forward primer contains a C
(bold italic) which is not present in the genomic sequence, and
was introduced to create the NcoI enzyme recognition site (i.e.
CCATGG) in the normal sequence. A transition from G to A
abolishes the NcoI site in the mutant allele.
PCR was performed in a final volume of 25 µl containing
40–50  ng  of  genomic  DNA,  0.2  mM  deoxynucleotide
triphosphates  (dNTPs),  1.5  mM  MgCl2,  0.2  µM  each  of
reverse and forward primer, 1× Taq buffer, and 1 U of Taq
polymerase. Polymerase chain reaction (PCR) was performed
in a thermal cycler by initial denaturation of the genomic DNA
at 95 °C for 7 min, followed by 35 cycles of denaturation at
95 °C for 30 s, primer annealing at 60 °C for 30 s, and chain
extension  at  72  °C  for  45  s.  A  final  extension  step  was
performed at 72 °C for 10 min.
The PCR product (12 µl) was subjected to restriction
enzyme  digestion  at  37  °C  overnight  with  10  U  of  NcoI
restriction  enzyme  according  to  the  manufacturer’s
instructions (Fermentas, Burlington, Ontario). The resulting
digested products were resolved on 4% agarose gels. PCR
products carrying the variant A allele remained uncut (212
bp), while PCR products carrying the wild-type G allele were
digested into two fragments of 192 bp and 20 bp.
TsIgE levels of patients and controls were determined
using  the  immunoglobulin  (IgE)  enzyme  immunoassay
quantitative test kit BC-1035 (BioCheck Inc., Foster City,
CA).  TsIgE  levels  of  all  the  patients  and  healthy  control
individuals were measured in duplicate.
A contingency table analysis (χ2 test) was performed to
determine the level of statistical association between genotype
and allele frequencies in patients and controls using StatCalc
from Epi Info, Version 6. TsIgE levels were expressed as
arithmetic or geometric means in IU/ml. To obtain a Gaussian
distribution, TsIgE levels were normalized by logarithmic
transformation  (Log10).  Statistical  computations  were  also
performed using Statistical Package for the Social Sciences
(SPSS  version  16).  A  p-value  <0.05  was  considered
statistically significant.
RESULTS
A  total  of  248  individuals  (122  PEXG  patients  and  126
unrelated healthy control individuals) were included in the
present  study.  The  PEXG  patients  had  a  mean  age  of
45.3±12.7 years and included 67% males and 33% females,
whereas the controls had a mean age of 44.2±12.3 years with
64% males and 36% females (Table 1).
The GG wild-type genotype was found at a frequency of
87% in the controls and 43% in the PEXG patients with an
odds ratio (OR) of 8.95 (95% confidence interval [CI]=4.55–
17.81; Table 1), whereas the number of heterozygous and
homozygous variant individuals was higher in patients as
compared  to  controls  (p<0.001,  χ2  54.97).  Of  the  PEXG
patients, 25% contained the AA variant genotype while in the
controls this genotype was present at only 2%, with OR=0.07
(95% CI=0.02–0.27). The GA heterozygous genotype was
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the controls were heterozygous (OR=0.24 [95% CI=0.12–
0.51]). The distribution of allele frequencies (Table 1) of the
patients  and  controls  showed  that  the  A  allele  was  more
prevalent in the PEXG patients (41%) as compared to controls
(8%) and was strongly associated with the disease condition,
OR=8.37 (95% CI=4.78–14.81; p<0.001, χ2 74.6).
The genotype distribution data were also stratified with
respect to gender to determine any gender bias (Table 1). Even
while considering the data of males and females separately,
the GA and AA genotypes remained significantly associated
with  PEXG,  (p<0.001,  χ2=33.30  and  p<0.001,  χ2=23.09,
respectively). In addition, the variant A allele was found to be
more prevalent in the PEXG male patients as well as female
patients when compared to the appropriate controls (p<0.001;
χ2=44.74, χ2=30.22, respectively). The frequency of the A
allele was found to be nearly the same in both sexes (40% and
43%, respectively; Table 1).
TsIgE  values  were  found  to  follow  a  log  normal
distribution in both the cohorts: controls and PEXG patients
(Table 2). No significant difference was found between the
TsIgE levels of PEXG patients and controls (Table 2A). In
addition, no significant difference was found when the Log10
TsIgE  values  of  the  different  genotypes  of  the  G-308A
polymorphism (GG, GA, and AA) of patients and controls
were compared (Table 2B).
DISCUSSION
During the last few years, several immunological components
have been shown to be involved in the pathogenesis of various
types of glaucoma. It has been observed that these components
are not usually the primary causative agents but are involved
in the progression of the disease [21,22]. In addition, it has
been  reported  that  components  of  the  immune  system
involved in the pathogenesis of glaucoma are also involved in
neurodegeneration  following  brain  injury.  In  such  cases
inflammation  occurs  in  response  to  glutamate,  reactive
oxygen  species  (ROS),  nitric  oxide  (NO),  and  cytokines
including tumor necrosis factor (TNF)-α, which are released
from activated microglia or macrophages [23]. As glaucoma
is a disease of old age and involves optic nerve neuropathy, it
has been proposed that both genetic as well as epigenetic
factors are involved in the progression of the disease. Such
factors cause a decrease in the cellular viability and self-
renewal  capacity,  which  results  in  the  generation  of
dysfunctional  microglia.  Such  age-related  attrition  may
TABLE 1. TNF-α G −308A GENOTYPE AND ALLELE FREQUENCY DISTRIBUTION BETWEEN PATIENTS AND CONTROLS.
  Controls (126) PEXG (122) OR (95% CI) p (χ2)
Mean age (years) 44.2±12.3 45.3±12.7
Gender distribution
Males 81 (64.3%) 82 (67.2%) 0.88 (0.50–1.54) 0.6 (0.24)
Female 45 (35.7%) 40 (32.8%)    
Genotype and allele frequency distribution
Genotypes (Males+Females)
GG 110 (87.3%) 53 (43.4%) 8.95 (4.55–17.81) <0.001 (54.97)
GA 13 (10.3%) 39 (32.0%) 0.24 (0.12–0.51)  
AA 3 (2.4%) 30 (24.6%) 0.07 (0.02–0.27)  
Alleles (Males+Females)
G 233 (92.5%) 145 (59.4%) 8.37 (4.78–14.81) <0.001 (74.61)
A 19 (7.5%) 99 (40.6%)    
Genotypes (Males)
GG 69 (85.2%) 36 (43.9%) 7.35 (3.27–16.79) <0.001 (33.30)
GA 11 (13.6%) 27 (32.9%) 0.32 (0.14–0.75)  
AA 1 (1.2%) 19 (23.2%) 0.04 (0.001–0.31)  
Alleles (Males)
G 149 (92.0%) 99(60.4%) 7.53 (3.79–15.19) <0.001 (44.74)
A 13 (8.0%) 65(39.6%)    
Genotypes (Females)
GG 41 (91.1%) 17 (42.5%) 13.87 (3.74–56.25) <0.001 (23.09)
GA 2 (4.4%) 12 (30.0%) 0.11 (0.02–0.58)  
AA 2 (4.4%) 11 (27.5%) 0.12 (0.02–0.66)  
Alleles (Females)
G 84 (93.3%) 46 (57.5%) 10.35 (3.78–29.81) <0.001 (30.22)
A 6 (6.7%) 34 (42.5%)    
Values in parentheses represent percentage.
Molecular Vision 2009; 15:2861-2867 <http://www.molvis.org/molvis/v15/a302> © 2009 Molecular Vision
2863contribute to the development of neurodegenerative diseases
by diminishing glial neurosupportive functions. Secondary
degeneration  by  the  immune  components  leads  to  the
neurodegenerative injury in glaucoma [24].
TNF-α is considered to be a neuroprotective component
of the immune system, because it activates the ubiquitous
transcription factor NF-κB through binding to the high affinity
TNF  receptor  (TNF-R2),  which  in  turn  mediates  the
expression of a wide range of genes essential for neuronal
survival. Contrary to its neuroprotective role, TNF-α can also
serve as a neurodegenerative factor when it binds to the low
affinity death receptor TNF-R1 and induces the mitochondria-
mediated apoptotic pathway [25–29]. Thus a delicate balance
between the two pathways determines the survival of the cell,
and any shift in equilibrium might have deleterious effects.
An  increased  expression  of  TNF-α  can  shift  the  balance
toward TNF-R1 signaling, as seen in glaucoma, and thus
promote  retinal  ganglion  cell  death.  Based  on  the  latter
observation,  an  antiglaucoma  drug,  GLC756,  has  been
developed that inhibits TNF-α release from activated rat mast
cells and thus promotes cell survival. This can be attributed to
the potential neuroprotective role of the compound (GLC756),
which  can  therefore  serve  an  important  role  in  the
management of glaucoma [30,31].
In the present study we found a strong association of GA
and AA genotypes with PEXG, suggesting a role of the A
allele in the pathogenesis of the disease. However, our results
are in contradiction with previous studies, which have shown
no  significant  association  of  the  TNF-α  polymorphism
G-308A  with  PEXG  in  both  Turkish  and  Caucasian
populations [32,33]. Agarwal et al. [34] reported that the G to
A transition at position −308 results in a six- to sevenfold
increase in transcription of TNF-α as compared to normal
basal level transcription, as a result of which increased levels
of TNF were observed. Recently, a significant association has
been observed for the G-308A polymorphism between PEXG
patients  and  controls  in  the  Iranian  population  (p<0.005)
[35], which is in agreement with our results. This similarity
with the Iranian population has also been observed for the
association of the ABO blood groups with different types of
glaucoma.  Blood  group  B  was  strongly  associated  with
different types of glaucoma [36], which is in agreement with
the study of Zaree et al. [37] in the Iranian population. Genetic
relatedness was also demonstrated previously in studies of the
Y chromosomal markers, which have shown that the Pakistani
populations  share  a  significant  similarity  in  their  genetic
makeup with different Iranian ethnic groups [38].
Our  results  are  in  accordance  with  the  findings  of
Razenghinejad  et  al.  [35],  and  are  interesting  for  several
reasons. In our study the statistically significant differences
between  patients  and  controls  are  more  pronounced  as
compared to the Iranian population, (<0.001 versus p=0.002).
We  attribute  this  difference  to  the  fact  that  we  not  only
observed a very high frequency of the heterozygous GA allele
compared to the Iranian study (32% versus 17%), but also
found  the  derived  AA  allele  at  a  much  higher  frequency
(24.6% versus 1.7%). Razenghinejad et al. [35] also noted that
when the data was stratified according to gender, the genotype
frequency became statistically insignificant for females, an
observation  that  they  attributed  to  the  unequal  gender
distribution in the study subjects. As opposed to the Iranian
study, we find that both the genotype and allele frequencies
remain significantly associated with the disease even after
gender-wise stratification (Table 1). A likely explanation is
that gender matching was better in our study than in the Iranian
study, thus emphasizing the importance of careful design of
genetic association studies.
A strong association of this polymorphism has also been
observed  in  the  Chinese  population,  but  that  study  was
performed  in  patients  with  primary  open-angle  glaucoma
(POAG) and with a very small sample size [20]. Although
several  investigators  were  unable  to  show  a  significant
difference  in  genotype  distribution  and  allele  frequency
between patients and control groups, some investigators have
TABLE 2. COMPARISON OF MEAN TSIgE LEVELS IN CONTROLS AND PATIENTS, AND AMONG DIFFERENT GENOTYPES OF TNF-α
POLYMORPHISM G −308A.
A. Comparison of mean log of TsIgE levels in controls and patients
TsIgE in IU/ml Controls (83) Mean±SD PEXG (40) Mean±SD p–value
  1.96±0.52 1.94±0.63 0.86
B. Comparison of log of TsIgE levels in genotypes of controls and patients
Genotypes Controls (83) Mean±SD Patients (40) Mean±SD p-value
GG 1.98±0.53 2.02±0.62 0.84
GA 1.76±0.47 2.06±0.64 0.2
AA 2.02±0.49 1.76±0.63 0.49
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2864successfully  demonstrated  the  functionality  of  this
polymorphism in the reporter gene assays with a significant
upregulation of up to fivefold in the constructs of TNF1 and
TNF2  alleles  [39].  This  suggests  that  transcriptional
regulation of TNF-α is essential to circumvent the deleterious
effects  of  overexpression  by  transcriptional  upregulation.
Thus  excessive  production  of  TNF  associated  with  the
G-308A polymorphism may have an important role in the
development of TNF2-associated autoimmune diseases, and
may act as a genetic susceptibility factor driven by a high
TNF-α expression, which would subsequently lead to immune
responses causing the onset of different diseases. A recent
study by Sawada et al. [40] also demonstrates that TNF-α
levels were significantly elevated in the aqueous humor of
PEXG patients as compared to controls and other glaucoma
subtypes, including POAG and normal tension glaucoma. We
believe that this is in line with our conjecture that TNF-α is
significantly involved in the pathogenesis of the disease in the
Pakistani population.
It is worth mentioning here that the greater number of
carriers with a GA genotype in the PEXG patients also points
toward the possibility of a dominant mode of inheritance of
the genetic defects responsible for PEXG. However, due to
the presence of such carriers in normal individuals, although
at  much  lower  frequency,  it  is  likely  that  environmental
influences  and  other  genetic  factors  contribute  to  the
development of the disease.
On the basis of different evidence it has been suggested
that autoimmune damage to the optic nerve may occur directly
by autoantibodies or indirectly by a “mimicked” autoimmune
response to a sensitizing antigen, which in turn injures retinal
ganglion cells [41]. In a recent study by Joachim et al. [22],
IgG antibody levels were found to be significantly higher in
the aqueous humor of patients with POAG and PEXG as
compared to controls, due to which it was concluded that
multiple factors contribute to the immune status of the eye
[22]. Therefore we also investigated the role of TsIgE levels
in  glaucoma  and  its  association  with  the  G-308A
polymorphism, as previously in a different disease it has been
shown  that  IgE  levels  were  associated  with  this  single
nucleotide polymorphism [42]. However, we did not find any
association of IgE levels with PEXG in our study population,
which could be because there is no significant involvement of
TsIgE levels in the manifestation and onset of the disease. This
warrants further investigation simultaneously in the serum
and aqueous humor of patients, as previously pointed out by
Joachim et al. [22].
In  conclusion,  we  find  the  A  allele  of  the  TNF-α
polymorphism G-308A to be strongly associated with the
pathogenesis of PEXG, and thus propose that the GA and AA
genotypes of the TNF-α regulatory region can be considered
genetic markers for the stratification of PEXG patients in
Pakistan. Mutations in TNF-α might be involved in causing
different  neurodegenerative  disorders,  therefore  it  is
important to consider it as a novel therapeutic target for the
treatment of neurodegenerative diseases like glaucoma. We
expect that our study will prove to be a helpful tool in the
treatment  and  management  of  PEXG  by  opening  up  new
horizons in the field of target discovery to develop novel
therapeutics.
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